Mesenchymal Stem Cells Market 2026 Growth Trends by Manufacturers, Regions, Type and Application, Forecast – Red & Black Student Newspaper
stemadminMesenchymal Stem CellsNo comments

The Mesenchymal Stem Cells Market is expected to have a highly positive outlook for the next eight years 2019-2026. This Research Reports emphasizes on key industry analysis, market size, Share, growth and extensive industry dynamics with respect to drivers, opportunities, pricing details and latest trends in the industry. The global Mesenchymal Stem Cells Market analysis further provides pioneering landscape of market along with market augmentation history and key development involved in the industry.

Read more
Stem Cell Therapy for Colon Cancer – Yahoo Finance
stemadminMesenchymal Stem CellsNo comments

WASHINGTON, April 2, 2020 /PRNewswire/ -- An article published in Experimental Biology and Medicine (Volume 245, Issue 6, March 2020) (https://journals.sagepub.com/doi/pdf/10.1177/1535370220910690) examines the safety of stem cell therapy for the treatment of colon cancer.The study, led by Dr. J. Liu in the State Key Laboratory of Bioreactor Engineering and Shanghai Key Laboratory of New Drug Design at the East China University of Science and Technology in Shanghai (China), reports that mesenchymal stem cells from a variety of sources promote the growth and metastasis of colon cancer cells in an animal model

Read more
MSC-based therapies from Mesoblast, Cynata advance to tackle COVID-19 ARDS – BioWorld Online
stemadminMesenchymal Stem CellsNo comments

PERTH, Australia Australian stem cell therapy company Mesoblast Ltd. announced that the FDA gave it the green light to test its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L in patients with acute respiratory distress syndrome (ARDS) caused by coronavirus (COVID-19). Were going to be evaluating whether an injection of our cells intravenously can tone down the immune system just enough so it gets rid of the virus but doesnt destroy your lungs at the same time, Mesoblast CEO Silviu Itescu told BioWorld.

Read more
Fluidigm CyTOF Technology Used to Evaluate Stem Cell Therapy as a Potential Treatment for COVID-19 Pneumonia – Yahoo Finance
stemadminMesenchymal Stem CellsNo comments

SOUTH SAN FRANCISCO, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation(FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Fluidigm CyTOF technology was used in a clinical study producing preliminary evidence that mesenchymal stem cell (MSC) therapy improves outcomes in patients with COVID-19 pneumonia, providing key information about potential mechanisms of action of the treatment strategy. Results of the study, conducted by researchers in China, have been published in Aging and Disease.1 We used a 36-marker CyTOF panel to generate a broad immune profile of each patients peripheral blood before and after transplantation, said Wenjing Wang, PhD, Associate Professor at Beijing Hepatology Research Institute, Youan Hospital. Mass cytometry allowed us to look at all immune populations of interest in a single tube of peripheral blood mononuclear cells, enabling us to use less sample and to simplify our workflow and analysis

Read more
All the COVID-19 vaccines and treatments currently in clinical trials – Digital Trends
stemadminMesenchymal Stem CellsNo comments

The coronavirus pandemic is a serious health risk, which is why countries around the world are racing to find vaccines and treatments. Nearly 1,000,000 cases of COVID-19 have been confirmed globally, and by the time you read this, the death toll will have surpassed 50,000. Some potential treatments listed here were previously in clinical testing for other diseases, such as cancer, allowing the trials for COVID-19 to be fast-tracked.

Read more

Theme: Illdy.